Back to Search Start Over

A novel disease-causing CD40L mutation reduces expression of CD40 ligand, but preserves CD40 binding capacity.

Authors :
Günaydin NC
Chou J
Karaca NE
Aksu G
Massaad MJ
Azarsiz E
Ertan Y
Geha RS
Kütükçüler N
Source :
Clinical immunology (Orlando, Fla.) [Clin Immunol] 2014 Aug; Vol. 153 (2), pp. 288-91. Date of Electronic Publication: 2014 May 17.
Publication Year :
2014

Abstract

Mutations in CD40 ligand (CD40L) that permit residual CD40L expression typically impair binding of CD40. We report a male patient who presented with recurrent bacterial respiratory tract infections, normal IgM, decreased IgG, absent IgA levels, and CD40L expression at ~50% of the level observed in the normal control. He subsequently developed autoimmunity, inflammatory bowel disease, severe opportunistic infections suggestive of a combined immunodeficiency, and a cervical spine schwannoma. Whole exome sequencing of the patient's genomic DNA revealed a novel missense mutation (p.H47Y) in CD40L. Although this mutation was predicted to be benign in silico, flow cytometry at 13 years of age demonstrated markedly decreased CD40L expression (~32% of normal control) that retained the capacity to bind soluble CD40-Ig, suggesting that the mutation impairs CD40L surface expression without affecting its affinity for CD40. This case highlights the variability in the clinical evolution and phenotype of CD40L deficiency.<br /> (Copyright © 2014 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1521-7035
Volume :
153
Issue :
2
Database :
MEDLINE
Journal :
Clinical immunology (Orlando, Fla.)
Publication Type :
Academic Journal
Accession number :
24845792
Full Text :
https://doi.org/10.1016/j.clim.2014.05.001